ArticleFrontiers in veterinary science2025
Comparison of 2.0 mg/kg/day and 0.5 mg/kg/day immunosuppressive dexamethasone protocols as initial treatment for dogs with MUO.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Canine meningoencephalitis of unknown origin (MUO) is a common immune-mediated neurological disorder primarily treated with corticosteroids. However, the optimal initial dosing regimen remains unclear. Method: This prospective, randomized, parallel-group study evaluated the short-term clinical efficacy and gastrointestinal (GIT) safety of two intravenous dexamethasone dosing protocols (0.5 mg/kg/day vs. 2.0 mg/kg/day) in dogs diagnosed with MUO. Neurological and GI scoring systems were used to assess outcomes over a four-day hospitalization period. Results: Sixty dogs were enrolled and randomly assigned to either the 0.5 mg/kg/day ( Discussion: This study has not identified a significant difference in short term outcome using different dosing protocols of dexamethasone in dogs diagnosed with MUO. Further studies with larger sample sizes and extended follow-up periods are warranted to investigate the potential dose-dependent effects of dexamethasone on both neurological and GIT outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.